The Sunday Roast

The Sunday Roast

Weekly stock banter and guest CEOs in the UK small-cap space. 

  1. 3d ago

    Midweek Takeaway with Colin Bird and Martyn Churchouse from Xtract Resources (AIM:XTR) #XTR

    This week on the Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Colin Bird and Martin Churchouse from Xtract Resources to discuss the company's transition from explorer to producer following the commencement of production at the Silver King Copper Project in Zambia. The discussion also covers progress at the KAS Antimony Project in Morocco, the move towards first concentrate production, underground and exploration plans, expansion opportunities across both projects, and why management believes Xtract is well positioned to generate long-term cash flow from its growing portfolio. Disclaimer & Declaration of InterestThis podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.

    Midweek Takeaway with Colin Bird and Martyn Churchouse from Xtract Resources (AIM:XTR) #XTR
  2. 6d ago

    The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAX

    Welcome to the Sunday Roast Midsummer Special! With the summer slowdown in full swing, Phil Carroll, Kevin Hornsby, and Charles Archer take a step back to discuss the biggest stories shaping the markets, politics, and the resource sector before the busy autumn period begins. Featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources, and Ajax Resources plc, the team explores the latest company developments, strategic updates, project progress, and the key themes driving investor interest ahead of what promises to be a busy autumn.  00:00 - 00:08:24 Intro00:08:24 #AFP Interview00:30:25 #POLB Interview00:55:15 #TM1 Interview01:10:47 #TAR Interview 01:23:16 #AJAX Interview01:41:10 Outro Disclaimer & Declaration of InterestThis podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.

    The Sunday Roast, Mid-Summer Special featuring African Pioneer, Poolbeg Pharma, Technology Minerals, Talon Resources and Ajax Resources plc #AFP #POLB #TM1 #TAR #AJAX
  3. Jul 15

    Midweek Takeaway featuring Jeremy Skillington and Cathal Friel from Poolbeg Pharma #POLB

    This week on the Midweek Takeaway, Kevin Hornsby is joined by Jeremy Skillington and Cathal Friel from Poolbeg Pharma to discuss the company's latest clinical milestone after dosing the first patient in its Phase II trial for POLB 001. The discussion covers how the treatment is designed to prevent cytokine release syndrome (CRS) in patients receiving cancer immunotherapies, the significance of Poolbeg's partnership with Johnson & Johnson, the commercial opportunity in a multi-billion-dollar market, and why management has continued to back the company with significant personal investment Disclaimer & Declaration of InterestThis podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.

    Midweek Takeaway featuring Jeremy Skillington and Cathal Friel from Poolbeg Pharma #POLB

Ratings & Reviews

4.7
out of 5
3 Ratings

About

Weekly stock banter and guest CEOs in the UK small-cap space. 

You Might Also Like